Ricardo Alvarez, Medical Director of the Breast Cancer Center & Director of Cancer Research, Cancer Treatment Centers of America (CTCA), Atlanta, GA, US, talks to touchONCOLOGY about the mutational landscape of metastatic cancers discovered from prospective clinical sequencing at a community practice cancer programme and the findings from the data he presented at ESMO 2018 in Munich, Germany. Dr Alvarez also discusses which type of patients are ideal candidates for next generation sequencing, and he highlights some of the limitations of precision medicine. Finally, Dr Alvarez gives us his throughs on the future of precision medicine and how this translate to clinical practice.
1. What proportion of cancer patients in your institution are receiving drugs matched to mutations in their tumours? (0:11)
2. Could you tell us a little about the data you are presenting from community practices? (0:48)
3. Which tumours are most amenable to this approach? (1:59)
4. What are the limitations of this approach? (2:43)
5. By how much do you expect the proportion of cancer patients receiving matched treatment to rise in the coming years? (3:42)
Speaker disclosures: Ricardo Alvarez has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018
Share this Video
Related Videos In Breast Cancer
Javier Cortés, ESMO 2021: Results of the Randomized Phase III DESTINY-Breast03 Study
touchONCOLOGY joins Dr Javier Cortés at ESMO 2021 to discuss the much-anticipated results of the randomized phase III DESTINY-Breast03 study. Questions 1. Why are antibody-drug conjugates needed in the treatment of HER2+ metastatic breast cancer? (00:17-01:17) 2. What were the objectives of the phase III DESTINY-Breast03 study? (01:17-01:55) 3. Could you tell us a little […]
Sara Tolaney, ASCO 2021: Abemaciclib in HR+, HER2+ high-risk early breast cancer
touchONCOLOGY joins Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss unmet needs and ongoing research in patients with early-stage HER2+ breast cancer. The abstract ‘eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer […]
Sara Tolaney, St. Gallen International Breast Cancer Conference 2021: Patient-reported outcomes from MonarchE
Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) joins touchONCOLOGY to discuss the patient-reported health-related quality-of-life outcomes data from the MonarchE trial (ClinicalTrials.gov Identifier: NCT03155997) in patients with HR+, HER2- breast cancer being treated with abemaciclib plus endocrine therapy. The e-poster ‘Patients’ quality of life and side effect perceptions in monarchE, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!